Australia is a world-leader in interstitial lung disease (ILD) research. Lung Foundation Australia are proud to partner with a collaborative national group of researchers to support registries, clinical trials and research programs.
A full overview of pulmonary fibrosis partnerships and programs can be found here
Research awards and grants program
To support emerging researchers, Lung Foundation Australia’s awards and grants program works with the CRE-PF through the CREATE (CRE-Advanced Training Environment) program to help early or mid-career PF researchers in their career development. Our awards and grants program works with the CRE-PF to help early or mid-career PF researchers. These grants support new, innovative research projects that will ultimately lead to:
- A better understanding of what causes PF, how many people have it, and its impact
- New ways to diagnose and treat PF
- Better outcomes and quality of life for people living with the disease.
These opportunities include:
- Fellowships and PhD scholarships
- Grants and awards
- Travel grants
Centre of Research Excellence in Pulmonary Fibrosis
The Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF), established in 2017 with NHMRC funding, plays a central role in building more research capacity to improve and extend the lives of people with PF. It fosters a national, coordinated research program focused on personalised diagnosis and treatment of fibrotic lung diseases. The CRE-PF also provides education and training for students, healthcare professionals, and researchers.
Australasian ILD Registry
The Australasian ILD Registry (AILDR) collects comprehensive data from ILD patients across Australia and New Zealand. This registry supports high-quality research and helps improve patient care by offering a valuable resource for understanding ILD.
Pulmonary Fibrosis Australasian Clinical Trials (PACT) network
The Pulmonary Fibrosis Australasian Clinical Trials (PACT) network connects specialists to design and conduct clinical trials aimed at improving outcomes for PF patients. It ensures that patients, families, and healthcare providers have access to the latest trial information and treatment innovations.
Australian Idiopathic Pulmonary Fibrosis Registry
The Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR), was finalised in 2022 active being for 10 years, and is now managed by the AILDR. This rich research platform has contributed significantly to understanding idiopathic pulmonary fibrosis (IPF). It has supported research into disease prevalence, progression markers, healthcare costs, and genetics. Its extensive data, including CT scans and blood samples, remains available for ongoing research.
Was this page helpful?
Good job! Please give your positive feedback
How could we improve this post? Please Help us.